These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1198 related articles for article (PubMed ID: 17062687)

  • 1. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.
    Kershaw MH; Westwood JA; Parker LL; Wang G; Eshhar Z; Mavroukakis SA; White DE; Wunderlich JR; Canevari S; Rogers-Freezer L; Chen CC; Yang JC; Rosenberg SA; Hwu P
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6106-15. PubMed ID: 17062687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor.
    Montagna D; Turin I; Schiavo R; Montini E; Zaffaroni N; Villa R; Secondino S; Schiavetto I; Caliogna L; Locatelli F; Libri V; Pession A; Tonelli R; Maccario R; Siena S; Pedrazzoli P
    Cytotherapy; 2012 Jan; 14(1):80-90. PubMed ID: 21942841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Possible Compartmental Cytokine Release Syndrome in a Patient With Recurrent Ovarian Cancer After Treatment With Mesothelin-targeted CAR-T Cells.
    Tanyi JL; Stashwick C; Plesa G; Morgan MA; Porter D; Maus MV; June CH
    J Immunother; 2017 Apr; 40(3):104-107. PubMed ID: 28234665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer.
    Koneru M; O'Cearbhaill R; Pendharkar S; Spriggs DR; Brentjens RJ
    J Transl Med; 2015 Mar; 13():102. PubMed ID: 25890361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model.
    Yoon SH; Lee JM; Cho HI; Kim EK; Kim HS; Park MY; Kim TG
    Cancer Gene Ther; 2009 Jun; 16(6):489-97. PubMed ID: 19096447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer.
    Kandalaft LE; Powell DJ; Coukos G
    J Transl Med; 2012 Aug; 10():157. PubMed ID: 22863016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer.
    Parker LL; Do MT; Westwood JA; Wunderlich JR; Dudley ME; Rosenberg SA; Hwu P
    Hum Gene Ther; 2000 Nov; 11(17):2377-87. PubMed ID: 11096442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive immunotherapy of epithelial ovarian cancer with Vγ9Vδ2 T cells, potentiated by liposomal alendronic acid.
    Parente-Pereira AC; Shmeeda H; Whilding LM; Zambirinis CP; Foster J; van der Stegen SJ; Beatson R; Zabinski T; Brewig N; Sosabowski JK; Mather S; Ghaem-Maghami S; Gabizon A; Maher J
    J Immunol; 2014 Dec; 193(11):5557-66. PubMed ID: 25339667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes.
    Lamers CH; Gratama JW; Warnaar SO; Stoter G; Bolhuis RL
    Int J Cancer; 1995 Feb; 60(4):450-7. PubMed ID: 7829257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody.
    Canevari S; Stoter G; Arienti F; Bolis G; Colnaghi MI; Di Re EM; Eggermont AM; Goey SH; Gratama JW; Lamers CH
    J Natl Cancer Inst; 1995 Oct; 87(19):1463-9. PubMed ID: 7674333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
    Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
    Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive T cell therapy for ovarian cancer.
    Gitto SB; Ihewulezi CJN; Powell DJ
    Gynecol Oncol; 2024 Jul; 186():77-84. PubMed ID: 38603955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells.
    Santin AD; Bellone S; Ravaggi A; Pecorelli S; Cannon MJ; Parham GP
    Obstet Gynecol; 2000 Sep; 96(3):422-30. PubMed ID: 10960637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes.
    Hwu P; Yang JC; Cowherd R; Treisman J; Shafer GE; Eshhar Z; Rosenberg SA
    Cancer Res; 1995 Aug; 55(15):3369-73. PubMed ID: 7614473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transduction of rIL-2 expanded CD4+ and CD8+ ovarian TIL-derived T cell lines with the G1Na (neor) replication-deficient retroviral vector.
    Nash MA; Platsoucas CD; Wong BY; Wong PM; Cottler-Fox M; Otto E; Freedman RS
    Hum Gene Ther; 1995 Nov; 6(11):1379-89. PubMed ID: 8573611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3.
    Lu YC; Parker LL; Lu T; Zheng Z; Toomey MA; White DE; Yao X; Li YF; Robbins PF; Feldman SA; van der Bruggen P; Klebanoff CA; Goff SL; Sherry RM; Kammula US; Yang JC; Rosenberg SA
    J Clin Oncol; 2017 Oct; 35(29):3322-3329. PubMed ID: 28809608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoptive cellular immunotherapy of human ovarian carcinoma xenografts in nude mice.
    Ortaldo JR; Porter HR; Miller P; Stevenson HC; Ozols RF; Hamilton TC
    Cancer Res; 1986 Sep; 46(9):4414-9. PubMed ID: 3089592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of chimeric antigen receptor-engineered T cells in ovarian cancer therapy.
    Zhang M; Zhang DB; Shi H
    Immunotherapy; 2017 Sep; 9(10):851-861. PubMed ID: 28877629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target.
    Perales-Puchalt A; Svoronos N; Rutkowski MR; Allegrezza MJ; Tesone AJ; Payne KK; Wickramasinghe J; Nguyen JM; O'Brien SW; Gumireddy K; Huang Q; Cadungog MG; Connolly DC; Tchou J; Curiel TJ; Conejo-Garcia JR
    Clin Cancer Res; 2017 Jan; 23(2):441-453. PubMed ID: 27435394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 60.